Skip to main content
Premium Trial:

Request an Annual Quote

Unilabs to Provide MDxHeath's Prostate Cancer Test in Europe

NEW YORK (360Dx) – MdxHealth announced today that it has entered into an agency service agreement with Unilabs for MDxHealth's SelectMDx urine test for prostate cancer.

Under the terms of the agreement, Unilabs will offer SelectMDx to patients of all its clinical labs in France, Portugal, Sweden, Norway, Denmark, Finland, UK, Italy, and Switzerland. Unilabs' medical laboratory in Geneva will perform the SelectMDx service testing. To offer the service throughout its network, Unilabs will purchase SelecMDx CE-market IVD kits from MDxHealth.

SelectMDx is a proprietary urine-based molecular diagnostic test that offers a noninvasive method to assess a man's risk for prostate cancer. The test delivers a negative predictive value of 98 percent for clinically significant disease.

"We are excited that Unilabs is going to offer SelectMDx service testing to their customers," said Jan Groen, CEO of MDxHealth. "The company's broad hospital network and commercial capabilities will significantly contribute to the successful market penetration of SelectMDx."